Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- 21 Jun 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 21 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jan 2017.
- 23 Sep 2015 New trial record